文献速递血栓与止血

VTE-PREDICT评分预测静脉血栓栓塞症复发与出血的外部验证:来自Registro Informatizado Enfermedad TromboEmbὀlica登记研究的结果

External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: results from the Registro Informatizado Enfermedad TromboEmbὀlica Registry.
PubMed 文献 · J Thromb Haemost · 2025-08-22

在Registro Informatizado Enfermedad TromboEmbὀlica前瞻性登记研究的17 850例静脉血栓栓塞症患者中外部验证VTE-PREDICT评分对复发与临床相关出血的预测能力。1年复发累积发生率3.7%(95%CI 3.4%-4.0%),临床相关出血2.6%(95%CI 2.4%-2.9%)。评分对复发判别良好(c统计量0.70-0.73),对临床相关出血判别中等(0.65-0.67),校准分析显示低估复发、高估出血风险。

要点

  • 17 850例患者中,1年静脉血栓栓塞症复发累积发生率3.7%(95%CI 3.4%-4.0%)。
  • 1年临床相关出血累积发生率2.6%(95%CI 2.4%-2.9%)。
  • VTE-PREDICT对复发判别良好、对临床相关出血判别中等,但高估高危患者复发风险。

核心结论

  • VTE-PREDICT对静脉血栓栓塞症复发判别良好、对临床相关出血判别中等,但低估了高危患者的静脉血栓栓塞症复发风险。

研究设计与样本

  • 研究为对Registro Informatizado Enfermedad TromboEmbὀlica前瞻性登记研究患者的外部验证,最终分析纳入17 850例患者(50.3%为女性),64.3%为肺栓塞,中位年龄67岁(IQR 52-78)。
  • 排除标准包括2012年前入组、活动性癌症以及使用直接口服抗凝药、维生素K拮抗剂或低分子肝素以外的抗凝治疗。
  • 预测期从索引静脉血栓栓塞症后3个月起至随后1至5年,计算静脉血栓栓塞症复发与临床相关出血(重大及临床相关非重大出血)风险,并与观察风险比较,评估c统计量与校准图。

主要发现

  • 1年静脉血栓栓塞症复发累积发生率为3.7%(95%CI 3.4%-4.0%),临床相关出血累积发生率为2.6%(95%CI 2.4%-2.9%)。
  • VTE-PREDICT对1至5年静脉血栓栓塞症复发的c统计量在0.70(95%CI 0.67-0.72)至0.73(95%CI 0.69-0.76)之间。
  • VTE-PREDICT对1至5年临床相关出血的c统计量在0.65(95%CI 0.63-0.67)至0.67(95%CI 0.64-0.70)之间。
  • 长期抗凝治疗方面,21.8%使用直接口服抗凝药,39.9%使用维生素K拮抗剂,4.8%使用低分子肝素,33.6%未接受抗凝治疗。
  • 校准分析显示低估静脉血栓栓塞症复发风险、高估临床相关出血风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The VTE-PREDICT score predicts venous thromboembolism (VTE) recurrence and clinically relevant bleeding (CRB; major and clinically relevant nonmajor bleeding) after acute VTE. OBJECTIVES: We aimed to externally validate the VTE-PREDICT score in the Registro Informatizado Enfermedad TromboEmbὀlica, a prospective registry of patients with VTE. METHODS: Exclusion criteria included enrollment before 2012, active cancer, and anticoagulation other than direct oral anticoagulants, vitamin K antagonists, or low-molecular-weight heparin. VTE recurrence and CRB risks were calculated using VTE-PREDICT for a prediction period of 3 months after the index VTE until the following 1 to 5 years. Predicted risks were then compared with observed risks. C-statistics and calibration plots were assessed. RESULTS: In total, 17 850 patients (50.3% women) were included in the final analysis, of whom 64.3% had pulmonary embolism. The median age was 67 years (IQR, 52-78). Regarding long-term anticoagulation, 21.8% of patients were treated with a direct oral anticoagulant, 39.9% with a vitamin K antagonist, and 4.8% with low-molecular-weight heparin, whereas 33.6% received no anticoagulant treatment. Cumulative incidences of VTE recurrence and CRB at 1 year were 3.7% (95% CI, 3.4%-4.0%) and 2.6% (95% CI, 2.4%-2.9%), respectively. The c-statistics of VTE-PREDICT for 1 to 5 years varied between 0.70 (95% CI, 0.67-0.72) and 0.73 (95% CI, 0.69-0.76) for VTE recurrence and between 0.65 (95% CI, 0.63-0.67) and 0.67 (95% CI, 0.64-0.70) for CRB. Calibration analysis revealed underestimation of VTE recurrence and overestimation of CRB risk. CONCLUSION: VTE-PREDICT showed good discrimination for VTE recurrence and moderate discrimination for CRB, but underestimated the risk of VTE recurrence in high-risk patients.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Hoberstorfer T, Nopp S, Steiner D, et al. External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: results from the Registro Informatizado Enfermedad TromboEmbὀlica Registry. J Thromb Haemost. 2025. PMID: 40850342. doi:10.1016/j.jtha.2025.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。